About Biocidium

Biocidium is clinical-stage biopharmaceutical company primarily focused on the discovery and development of novel antibiotics and antifungals for the treatment of serious multi-drug resistant (MDR) gram-positive and gram-negative bacterial and fungal infections. Biocidium remains focused on its cancer and dermatology programs with a current dedication towards skin cancer.

Biocidium’s four core platforms:

Antibiotics – Gram-positive and Gram-negative – The ever-increasing resistance to marketed antibiotics has led to a clear need for novel anti-infective agents that are active against MDR. Biocidium’s proprietary high efficacy/low toxicity antibiotics represent innovative advances in a comprehensive solution to combating these harmful diseases. The global systemic antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%.

Antifungals – The global market for human antifungal therapeutics is expected to grow to nearly $13.9 billion by 2018, with a five-year growth rate (CAGR) of 3.2%.

Cancer – Skin Melanoma and broad spectrum multiple cancer treatment. The cancer drugs and treatments market will reach $143.7bn by 2023, a compound annual growth rate of 20%+.

Dermatology – Shingles, Psoriasis and Eczema. The global skin care products market is expected to grow at a compound annual growth rate of 4.8% from 2021 to 2028 to reach USD $188.24 billion by 2028.

Biocidium’s most advanced developments:

BCM-0184 – Novel antibiotic – Phase 1 clinical – MRSA (methicillin resistant Staphylococcus aureus),
BCM-0882 – Novel antifungal – Preclinical trials – Candida auris (Antimicrobial Resistant)
BCM-0915 – Novel antifungal – Preclinical trials – Candida albicans (Antimicrobial Resistant)
BCM-0241 – Novel antibiotic – Preclinical trials – VRE (vancomycin resistant Enterococcus),
BCM-0316 – Novel antibiotic – Preclinical trials – CRE (carbapenem-resistant Enterobacteriaceae).
BCM-0316 – Novel antibiotic – Preclinical trials – VRSA (Vancomycin-resistant Staphylococcus aureus).
BCM-0316 – Novel antibiotic – Preclinical trials – DRNG (Drug-resistant Neisseria gonorrhoeae)
BCM-0316 – Novel antibiotic – Preclinical trials – MDPA (Multidrug-resistant Pseudomonas aeruginosa)
BCM-0316 – Novel antibiotic – Preclinical trials – DRS (Drug-resistant Shigella)

Biocidium has multiple additional projects in pre-clinical development and its multi-disciplined discovery capability is expected to generate additional novel product candidates to further address the major issues of antibiotic resistance.

Through its Canadian and US laboratories Biocidium will continue to add to its IP portfolio and focus on developing treatments for a range of infections, diseases and conditions.

Scientific Advisory Board

David M. Aronoff, MD, FIDSA, FAAM

Addison B Scoville, Jr Chair in Medicine
Director, Division of Infectious Diseases
Department of Medicine
Department of Pathology, Microbiology & Immunology

David Aronoff, MD is Professor and Addison B Scoville, Jr Chair in Medicine and Director of the Division of Infectious Diseases at the Vanderbilt University School of Medicine. He is a Fellow in the Infectious Diseases Society of America and a Fellow in the American Academy of Microbiology. He received his Bachelor of Science degree in Microbiology from Indiana University and his Medical Degree at Tufts University in Boston. He completed internship and residency training in Internal Medicine at Vanderbilt University. Dr. Aronoff stayed at Vanderbilt to complete a clinical fellowship in Infectious Diseases and a research fellowship in Clinical Pharmacology. He then joined the faculty in Infectious Diseases at the University of Michigan where he also completed a research postdoctoral fellowship in Immunology. Dr. Aronoff remained at the University of Michigan until 2013, rising to the rank of Associate Professor with tenure in the Departments of Internal Medicine and Microbiology & Immunology. He returned to Vanderbilt in October, 2013.

The Aronoff research lab studies serious bacterial infections, particularly those involving the reproductive tract and gastrointestinal system. Dr. Aronoff has received numerous governmental and non-governmental research grants. He has published more than 160 peer-reviewed manuscripts, and several book chapters and invited commentaries.